NYSE ARCA | ETF
Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index.
The index seeks to track the performance of the common stock ofU. S. exchange-listed biotechnology companies with a primary product offering (lead drug) that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval.
Top 20 Holdings
| Asset | Name | Sector | Industry | Weight |
|---|---|---|---|---|
| ALPN | Alpine Immune Sciences Inc | Healthcare | Biotechnology | 2.68% |
| LBPH | Longboard Pharmaceuticals Inc | Healthcare | Biotechnology | 2.54% |
| NVAX | Novavax Inc | Healthcare | Biotechnology | 2.12% |
| GERN | Geron Corporation | Healthcare | Biotechnology | 1.84% |
| 6XC | SOLENO THERAPEUT. DL-001 | Healthcare | Biotechnology | 1.76% |
| MORF | Morphic Holding Inc | Healthcare | Biotechnology | 1.74% |
| VERV | Verve Therapeutics Inc | Healthcare | Biotechnology | 1.55% |
| KRYS | Krystal Biotech Inc | Healthcare | Biotechnology | 1.28% |
| NK | NantKwest Inc | Healthcare | Biotechnology | 1.23% |
| RGNX | Regenxbio Inc | Healthcare | Biotechnology | 1.10% |
| KRTX | Karuna Therapeutics Inc | Healthcare | Biotechnology | 1.10% |
| CBAY | Cymabay Therapeu | Healthcare | Biotechnology | 1.09% |
| PHAT | Phathom Pharmaceuticals Inc | Healthcare | Biotechnology | 1.06% |
| PRTA | Prothena Corporation plc | Healthcare | Biotechnology | 1.05% |
| INBX | Inhibrx Inc | Healthcare | Biotechnology | 1.04% |
| NTLA | Intellia Therapeutics Inc | Healthcare | Biotechnology | 0.98% |
| ZYME | Zymeworks Inc. Common Stock | Healthcare | Biotechnology | 0.98% |
| MDGL | Madrigal Pharmaceuticals Inc | Healthcare | Biotechnology | 0.98% |
| CNTA | Centessa Pharmaceuticals PLC ADR | Healthcare | Biotechnology | 0.95% |
| ABCL | Abcellera Biologics Inc | Healthcare | Biotechnology | 0.95% |